Skip to main content
BioMarin's hemophilia A gene therapy could cost between $2M and $3M

BioMarin Pharmaceutical announced that it is considering a price between $2 million and $3 million for its gene therapy Valrox, or valoctocogene roxaparvovec, a treatment for hemophilia A. BioMarin is also considering other payment options such as pay for performance.

Full Story: